Bronchial Biopsy Devices Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

Bronchial biopsy devices are a focused segment within the broader respiratory diagnostics and interventional pulmonology market, supporting the sampling of suspicious lesions in the tracheobronchial tree. Global revenues are estimated near USD 480 million in 2025, with industry projections pointing to USD 710 million by 2030, reflecting a steady mid-single-digit expansion. The segment sits inside a wider biopsy devices market valued at about USD 2.35 billion in 2025, indicating that bronchial applications represent a meaningful but specialized share of total sampling-instrument sales.

• •2025 market size: approximately USD 480 million; 2030 projection: about USD 710 million.
• •Forecast CAGR of 6.8% from 2025 to 2030, consistent with the 6.4%-6.9% range reported across independent industry analyses.
• •Bronchial biopsy devices are a sub-segment of the broader USD 2.35 billion global biopsy devices market.

Rising global incidence of lung cancer and increased adoption of low-dose CT screening programs are generating more referrals for tissue confirmation, directly lifting procedural volumes for bronchial biopsy. Healthcare systems are also shifting toward minimally invasive diagnostics, which favor bronchoscopic sampling over surgical approaches. Parallel improvements in imaging guidance, endoscope design, and ancillary tools are making transbronchial and endobronchial biopsies safer and more diagnostically reliable, further supporting device uptake.

• •Expanded lung-cancer screening is increasing the number of suspicious pulmonary lesions requiring tissue diagnosis.
• •Minimally invasive bronchoscopic sampling is being preferred over more invasive surgical biopsy procedures.
• •Advances in navigation, imaging, and robotic bronchoscopy are improving diagnostic yield and clinician confidence.

The market can be segmented by product type, primarily biopsy forceps, transbronchial needles, cytology brushes, and associated accessories, and by usage pattern, with disposable instruments gaining share over reusable variants. Disposable and reusable biopsy forceps together account for a substantial portion of segment value, estimated near USD 390 million in 2025 for forceps-based products. North America leads in revenue contribution due to high screening rates and advanced hospital infrastructure, while Europe represents a mature second market; Asia-Pacific is the fastest-growing region as healthcare access, smoking-related disease burden, and procedural capacity expand.

• •Forceps, needles, and cytology brushes are the principal product categories within the market.
• •Disposable devices are gaining share relative to reusable instruments on infection-control grounds.
• •North America holds the largest share, with Asia-Pacific identified as the fastest-growing regional market.

What are the recent trends and outlook?

Through 2030, the market is expected to continue expanding at a mid-to-high single-digit CAGR, closely tracking the 6.5%-6.9% range reported across adjacent bronchoscopy and biopsy-device forecasts. Robotic-assisted bronchoscopy is emerging as a structural growth driver, improving access to peripheral lesions and raising demand for compatible biopsy tools. Additional momentum is likely from AI-enabled image analysis, broader reimbursement for lung-cancer screening, and continued migration from reusable to disposable instrument formats in hospital and ambulatory settings.

• •Robotic bronchoscopy platforms are creating a new generation of compatible biopsy instruments and accessories.
• •AI-assisted lesion detection and navigation is expected to increase diagnostic yield per procedure.
• •Continued transition from reusable to disposable biopsy devices supports steady volume growth in consumables.